Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: A subanalysis from the Home-LITE study

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 476-481

  Hull, Russell D ^a   Liang, Jane ^a   Merali, Tazmin ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Intelligent Management Inc   (Canada)

Author keywords

iliac vein; low molecular weight heparin; postthrombotic syndrome; tinzaparin; venous thrombosis

Indexed keywords

TINZAPARIN; WARFARIN;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; ILIAC VEIN THROMBOSIS; INCIDENCE; LEG ULCER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

ILIAC VEIN; LOW-MOLECULAR-WEIGHT HEPARIN; POSTTHROMBOTIC SYNDROME; TINZAPARIN; VENOUS THROMBOSIS;

COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; POSTTHROMBOTIC SYNDROME; PROGNOSIS; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS; WARFARIN;

EID: 84884265697     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613481845     Document Type: Article

References (27)

1. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008 ; 149 (10). 698-707
2. Jenkins JS. Endovascular therapies to treat iliofemoral deep venous thrombosis. Prog Cardiovasc Dis. 2011 ; 54 (1). 70-76
3. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med. 2001 ; 110 (7). 515-519
4. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2). e419S - e494S
5. Kahn SR, Kearon C, Julian JA, et al. Extended Low-intensity Anticoagulation for Thrombo-embolism (ELATE) Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005 ; 3 (4). 718-723
6. Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspect Vasc Surg Endovasc Ther. 2009 ; 21 (4). 221-224
7. Enden T, Kløw NE, Sandvik L, et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009 ; 7 (8). 1268-1275
8. Comerota AJ, Throm RC, Matthias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg. 2000 ; 32 (1). 130-137
9. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 ; 122 (8). 762-769
10. Hull R, Butcher P. Value of patient self-assessment in the diagnosis and monitoring of post-thrombotic syndrome: the Patient-Tracked Symptoms Questionnaire. Clin Appl Thromb Hemost. 2012 ; 18 (4). 345-350
11. Carpenter JP, Holland GA, Baum RA, Owen RS, Carpenter JT, Cope C. Magnetic resonance venography for the detection of deep venous thrombosis: comparison with contrast venography and duplex Doppler ultrasonography. J Vasc Surg. 1993 ; 18 (5). 734-741
12. Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008 ; 112 (3). 511-515
13. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 ; 119 (12). 1062-1072
14. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996 ; 334 (11). 677-681
15. Koopman M, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996 ; 334 (11). 682-687
16. Kent D, Lindenauer PK. Aggregating and disaggregating patients in clinical trials and their subgroup analyses. Ann Intern Med. 2010 ; 153 (1). 51-52
17. Vedantham S, Millward SF, Cardella JF, et al. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Radiol. 2006 ; 17 (4). 613-616
18. Broholm R, Panduro Jensen L, Baekgaard N.. Catheter-directed thrombolysis in the treatment of iliofemoral venous thrombosis. A review. Int Angiol. 2010 ; 29 (4). 292-302
19. Watson L, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2004 ; ( 4 ):
20. Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis vs. standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012 ; 379 (9810). 31-38
21. Lee A, Levine M, Baker R, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349 (2). 146-153
22. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med.. 2007 ; 120 (1). 72-82
23. Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011 ; 124 (8). 756-765
24. Daskalopoulos ME, Daskalopoulo SS, Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomised trial. Eur J Vas Endovasc Surg. 2005 ; 29 (6). 638-650
25. Gervasi GB, Farina C, Catalani R, Bartoli C. Baldacci M. 'In vitro' fibrinolytic activity of a new low molecular weight heparan sulphate. Thromb Res. 1990 ; 59 (6). 931-939
26. Bacher P, Welzel D, Iqbal O, et al. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res. 1992 ; 66 (2-3). 151-158
27. Villalta S, Bagatella P, Piccioli A, et al. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis. 1994 ; 24 (suppl 1). 158a